Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early surfactant administration in newborns at or above 35 weeks gestation with respiratory distress
2009-016608-22Phase 2Active
- Sponsor
- CHU Amiens-Picardie
- Start
- Nov 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of Poractant alfa in respiratory distress syndrome (RDS), sponsored by CHU Amiens-Picardie. Primary endpoint: Oxygen therapy definition for primary endpoint. Started Nov 2009; status: active.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2009-016608-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016608-22.